Renewal Bio
Tel Aviv, Israel· Est.
Synthetic embryo platform enabling next‑generation disease models and drug screening.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Synthetic embryo platform enabling next‑generation disease models and drug screening.
Regenerative MedicineDisease ModelingToxicologyNeurodevelopment
Technology Platform
Synthetic embryo platform using naïve pluripotent stem cells to generate ex‑utero embryo‑like structures for high‑fidelity developmental modeling.
Opportunities
Scaling the embryo platform for high‑throughput drug screening and expanding disease‑specific models can unlock new revenue streams and strategic pharma collaborations.
Risk Factors
Technical reproducibility at scale, ethical scrutiny, and regulatory acceptance of synthetic embryo models could impede commercialization.
Competitive Landscape
Key competitors include Cellarity, Mosaic, and Celsius Therapeutics; Renewal Bio differentiates through its focus on early embryogenesis and cross‑species embryo models.